Delaying prostate cancer radiation therapy offers room for flexibility in pandemic peak

August 13, 2020

For cancer patients receiving radiation treatment during a surge in COVID-19 cases, adhering to the stay-at-home orders of quarantine is not always an option. The daily hospital trips potentially increase exposure, which is especially dangerous because cancer patients are at high risk for COVID-19 mortality. The option to delay radiation therapy until COVID-19 cases flatten could help cancer patients minimize exposure to the virus by staying home. A new study by investigators from Brigham and Women's Hospital found that for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, delaying radiation while remaining on hormone therapy is unlikely to impact survival. Their results are published in JAMA Oncology.

"Using a large database of patients with prostate cancer, we validated that the timing of starting radiation could be flexible," said Vinayak Muralidhar, MD, a resident in the Department of Radiation Oncology at the Brigham. "Our data suggest that patients can wait for COVID-19 cases to go down before starting radiation. Or, if there's a chance a surge is coming, they could consider undergoing radiation a little earlier than planned and complete it before the surge arrives."

"Our hope is that our study helps patients and providers make decisions about the timing of treatment," said Edward Christopher Dee, a fourth-year student at Harvard Medical School who was the first author of the study. "These decisions may allow patients to decrease their risk of exposure to COVID-19. Our findings may also provide reassurance to patients and providers who choose to delay treatment."

Radiation therapy is used for patients with localized prostate cancer and is given with 6-to-36 months of androgen deprivation therapy, or hormone therapy. Based on preclinical data, these two types of therapy are typically timed so that patients receive radiation treatment after two months of hormone therapy. However, two trials looking at this sequence of therapy showed that within a small window, exact timing of starting radiation relative to starting hormone therapy did not affect the outcome. The Brigham investigators wanted to validate the findings of these two relatively small trials in a cohort of over 63,000 cases of localized prostate cancer in the National Cancer Database. With this type of data set, the team recognizes there could be unmeasured differences between the patients that were not accounted for but explain the findings.

The cases were separated into four groups based on when radiation was started relative to hormone therapy. For cases of intermediate and high-risk disease, there was no difference in overall survival among the four groups.

"The findings are reassuring to patients and allow us to come up with a flexible radiation schedule for prostate cancer that ensures their safety," said Muralidhar. "The results have important implications for patients in areas experiencing a surge in COVID-19 cases who can opt to wait for a safer time to come in and initiate treatment. In the future, we can also look at other types of cancers and treatments and see how delaying therapy has an impact on survival."
Funding for this work was provided by the National Cancer Institute (grant number R01-CA240582).

Paper cited: Dee, EC et al. "Timing of Radiation and Androgen Deprivation for Prostate Cancer: Implications for Treatment during the COVID-19 Pandemic" JAMA Oncology DOI: 10.1001/jamaoncol.2020.3545

Brigham and Women's Hospital

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to